Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer - Concepedia

Concepedia

Publication | Open Access

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

DOI Full Paper Access

27

Citations

30

References

2022

Year

Milan Radovich, Jeffrey P. Solzak, Chao J. Wang, Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria Storniolo, Tarah J. Ballinger, Bryan P. Schneider,

Clinical Cancer Research

Abstract

The combination of gedatolisib + cofetuzumab pelidotin was well tolerated and demonstrated promising clinical activity. Further investigation of this drug combination in metastatic TNBC is warranted.

References

	Year	Citations

Page 1